|
Oct 8
|
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
|
|
Oct 4
|
OncoCyte Secures Funding Through Private Share Sale
|
|
Oct 2
|
Oncocyte Signs Leading Transplant Centers in US and Germany
|
|
Oct 2
|
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
|
|
Jun 24
|
Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move
|
|
May 30
|
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
|
|
May 15
|
Oncocyte Reports First Quarter 2024 Financial Results
|
|
May 13
|
Oncocyte to Announce First Quarter 2024 Financial Results
|
|
May 7
|
PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace
|
|
Apr 12
|
Oncocyte Reports Full Year 2023 Financial Results
|
|
Apr 12
|
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
|
|
Apr 11
|
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
|
|
Apr 9
|
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results
|
|
Jan 16
|
Oncocyte to Present at the Sequire Investor Summit in Puerto Rico
|
|
Dec 6
|
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays
|
|
Nov 3
|
Oncocyte to Announce Third Quarter 2023 Financial Results
|
|
Apr 27
|
Oncocyte To Announce First Quarter 2023 Financial Results
|